The Valley Desk

ArticleDermatology and therapyPublished

Efficacy and Safety of the PD-1 Agonist JNJ-67484703 in Participants with Atopic Dermatitis: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial Results

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Dermatology and therapy
Published
Subject terms
Pharmacodynamics; Atopic Dermatitis; Programmed Cell Death Protein 1; Jnj-67484703
PubMed ID
42008057
PubMed Central ID
PMC13237295
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal